Our Mission

Mission Statement

MAPS Public Benefit Corporation (MAPS PBC) catalyzes healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics prioritizing public benefit above profit. Founded in 2014, MAPS PBC is a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS) a 501(c)(3) nonprofit.

Public Benefit

What is the Benefit of a Public Benefit Corporation?

 

Shared Guiding Principles

Patients First. Learn About Our Purpose and Mission.

Who We Are

We Strive for Public Benefit. We Are the Members of MAPS PBC. 

What is a Public Benefit Corporation?

A Public Benefit Corporation is a new type of corporation that is driven by values that promote sustainability, accountability, and transparency.

  • Sustainability: We use profits to continue research to benefit society.
  • Accountability: We take our impact on society and the environment into consideration.
  • Transparency: We are required to report and share progress towards our impact on society.

Our Relationship to MAPS

MAPS Public Benefit Corporation (MAPS PBC), is a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS).

The Mission of MAPS

Founded in 1986, the Multidisciplinary Association for Psychedelic Studies (MAPS) is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana.

Shared Guiding Principles

  • Patients first and profits for care – Accessible mental health treatments for those who are in need.
  • Transparency — Commitment to open-science principles.
  • Passion and Perseverance — We persist in the face of challenges.
  • Intelligent Risk — Our decisions are informed by research.
  • Trust and Accountability — We value integrity and honesty, and embrace high standards.

*MAPS Public Benefit Corporation is owned by one shareholder.

MAPS PBC is Committed to Collective Liberation

MAPS PBC is committed to collective liberation. We acknowledge the existence of historic and systemic oppression and recognizes that a truly liberated future can only exist if all people, including and especially those who have been impacted by these injustices, are included in its creation. Collective liberation recognizes that all of our struggles are intimately connected, and that within systems of oppression, everyone suffers.

Who We Are

MAPS Public Benefit Corporation

Established in 2014

Come work with us!

Board of Directors

Amy Emerson

Amy Emerson Executive Director & Head of Clinical Development and Regulatory Affairs

Read Bio
Amy Emerson

Amy Emerson

Executive Director & Head of Clinical Development and Regulatory Affairs

Amy Emerson is the Executive Director and Head of Clinical Development and Regulatory Affairs at the MAPS Public Benefit Corporation (MAPS PBC), a wholly owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), a 501(c)(3) non-profit. As the Executive Director, Amy has lead the growth and development of this new subsidiary and is responsible for overall global regulatory strategy and implementation of research programs with a focus on the MDMA-assisted psychotherapy program within MAPS PBC.

Amy started as a pro bono consultant at MAPS in 2003, and since then has built MAPS’ clinical department while managing the MDMA Clinical Development Program with a focus on the PTSD indication. In 2014, MAPS Public Benefit Corporation was incorporated to focus on psychedelic drug development, therapist training programs, and future sales of prescription psychedelics prioritizing public benefit above profit.

Amy brings decades of pharmaceutical development and research experience in Phase 1 through Phase 3 Randomized Controlled Trials including supporting three successful regulatory approvals for new biologics. Her professional experience at Novartis, Chiron and other pharmaceutical companies (1993-2009) spans various fields including immunology, oncology and vaccines. Pursuing her love of science and nature cultivated while growing up in the woods of Alaska she earned her B.S. in genetics and cell biology from Washington State University in 1992 to prepare for a career in research. Amy is passionate about being a mother and the work of bringing the potential of psychedelics for healing further into the consciousness of the world, leaving a better world for the following generations. She has a lifelong love of travel, living abroad with her husband, exploring in nature and cooking with her family.

 

 

 

Rick Doblin, Ph.D.

Rick Doblin, Ph.D.

Rick Doblin, Ph.D., is the founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS). He received his doctorate in Public Policy from Harvard's Kennedy School of Government, where he wrote his dissertation on the regulation of the medical uses of psychedelics and marijuana and his Master's thesis on a survey of oncologists about smoked marijuana vs. the oral THC pill in nausea control for cancer patients. His undergraduate thesis at New College of Florida was a 25-year follow-up to the classic Good Friday Experiment, which evaluated the potential of psychedelic drugs to catalyze religious experiences. He also conducted a thirty-four year follow-up study to Timothy Leary's Concord Prison Experiment. Rick studied with Dr. Stanislav Grof and was among the first to be certified as a Holotropic Breathwork practitioner. His professional goal is to help develop legal contexts for the beneficial uses of psychedelics and marijuana, primarily as prescription medicines but also for personal growth for otherwise healthy people, and eventually to become a legally licensed psychedelic therapist. He founded MAPS in 1986, and currently resides in Boston with his wife and empty rooms from three children who are all in college.

Dawn McCollough

Dawn McCollough

Dawn McCollough has overseen global clinical development involving thousands of patients across numerous indications for nearly 25 years.  In addition to her role at MAPS PBC, she owns a consulting company that assists pharmaceutical, biotech and CRO clients.

Previously, she headed clinical operations functions in start-up Biotech organizations, headed Medical Research Operations and Research Team in Late Stage Development at Biogen. Prior to that, Dawn was Head of the Global Monitoring Organization for North America at Novartis Vaccines and Diagnostics, based in Cambridge, MA. Dawn began her career with Novartis as Global Head of Clinical Trial Governance based in Siena, Italy. Throughout the course of her career, she has participated in the development of numerous drug products from concept to approval. Dawn has been chosen as a top Women’s Leader within previously affiliated organizations.

Dawn has an entrepreneurial spirit and is passionate about developing new options for patients and for people. Dawn enjoys ultra running and has a very strong connection with animals, and anything outdoors.

 

 

Matt Neal

Matt Neal

Matthew J. Neal currently works as the Sr. Director of Product Management in Regulatory Solutions at PAREXEL. He previously spent mor ethan a decade at Amgen, Inc. as Director of Operations in Global Regulatory Affairs and Safety with a focus on Human Therapeutics to dramatically improve people’s lives. Prior to that, he lived in Philadelphia where he was one of the pioneering members of the Regulatory Submissions Department for GlaxoSmithKline. Matthew has been publishing and submitting electronic dossiers to the FDA since 1996, and submitted the very first fully electronic NDA for GSK in 1999. Matthew holds a Master's Degree in Communication from Temple University. He and his wife Beth spend most of their time entertaining their 8 year-old daughter, Claudia, their 4 year-old son, Tobias and their dog, Matilda. Matthew also performs stand-up comedy all over Los Angeles (mattnealcomedy.com), writing and producing various projects, travel, surfing, running, playing golf, and playing the drums in the improv jazz duo Mr. Driscoll and other studio projects (http://marinernine.bandcamp.com) He is also a member of the Founders Circle for the non-profit music engine weathervanemusic.org

 

Our Directors

Amy Emerson

Amy Emerson Executive Director & Head of Clinical Development and Regulatory Affairs

Read Bio
Amy Emerson

Amy Emerson

Executive Director & Head of Clinical Development and Regulatory Affairs

Amy Emerson is the Executive Director and Head of Clinical Development and Regulatory Affairs at the MAPS Public Benefit Corporation (MAPS PBC), a wholly owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), a 501(c)(3) non-profit. As the Executive Director, Amy has lead the growth and development of this new subsidiary and is responsible for overall global regulatory strategy and implementation of research programs with a focus on the MDMA-assisted psychotherapy program within MAPS PBC.

Amy started as a pro bono consultant at MAPS in 2003, and since then has built MAPS’ clinical department while managing the MDMA Clinical Development Program with a focus on the PTSD indication. In 2014, MAPS Public Benefit Corporation was incorporated to focus on psychedelic drug development, therapist training programs, and future sales of prescription psychedelics prioritizing public benefit above profit.

Amy brings decades of pharmaceutical development and research experience in Phase 1 through Phase 3 Randomized Controlled Trials including supporting three successful regulatory approvals for new biologics. Her professional experience at Novartis, Chiron and other pharmaceutical companies (1993-2009) spans various fields including immunology, oncology and vaccines. Pursuing her love of science and nature cultivated while growing up in the woods of Alaska she earned her B.S. in genetics and cell biology from Washington State University in 1992 to prepare for a career in research. Amy is passionate about being a mother and the work of bringing the potential of psychedelics for healing further into the consciousness of the world, leaving a better world for the following generations. She has a lifelong love of travel, living abroad with her husband, exploring in nature and cooking with her family.

 

 

 

Berra Yazar-Klosinski, Ph.D.

Berra Yazar-Klosinski, Ph.D. Director of Research Development and Regulatory Affairs at MAPS

Read Bio
Berra Yazar-Klosinski, Ph.D.

Berra Yazar-Klosinski, Ph.D.

Director of Research Development and Regulatory Affairs at MAPS

Berra Yazar-Klosinski, Ph.D., is the Director of Research Development and Regulatory Affairs of the 501(c)(3) non-profit Multidisciplinary Association for Psychedelic Studies (MAPS). Dr. Yazar-Klosinski is responsible for development of strategic, catalytic, and capacity-building activities to facilitate research on the risk/benefit profile of psychedelics in compliance with the global regulatory landscape. She has been actively involved in the various stages of nonclinical and clinical development of MDMA-assisted psychotherapy, LSD-assisted psychotherapy, cannabis, and ibogaine.

After gaining experience in clinical research laboratories with Geron Corporation and Millennium Pharmaceuticals, Dr. Yazar-Klosinski joined MAPS in 2009 to work with an organization where profit wouldn't dictate the agenda of scientific research. Over the last 10 years, she has supported MAPS clinical research and regulatory affairs through all stages of growth. Dr. Yazar-Klosinski has developed a strong track record of success with FDA, state regulatory agencies and multiple regulatory agencies outside of the USA.

Dr. Yazar-Klosinski earned her B.S. in Biology with a minor in Drama from Stanford University and her Ph.D. in Molecular, Cell, and Developmental Biology from the University of California, Santa Cruz in 2010. She is a Turkish hunter-gatherer who is supporting the growth of her family and pets in harmony with the natural world as she works tirelessly to transform the future.

Rebecca Matthews

Rebecca Matthews Director of Clinical Operations

Read Bio
Rebecca Matthews

Rebecca Matthews

Director of Clinical Operations

Rebecca Matthews is the Associate Director of Clinical Operations at the MAPS Public Benefit Corporation (MAPS PBC), a wholly owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), a 501(c)(3) non-profit. Rebecca is leading the Clinical Operations teams in conducting clinical trials around the globe in all indications and clinical programs supported by MAPS PBC and MAPS.

Rebecca began consulting with MAPS in 2009 and joined MAPS PBC full-time in 2015. Prior to her work at MAPS and MAPS PBC she worked in clinical research and development at Chiron/Novartis starting in 2001 with a focus in the indications of sepsis and vaccines.

Rebecca is drawn to the field of research and drug development to support the advancement of healthcare and to provide novel and improved treatments for the benefit of humankind. She is deeply passionate about this amazing journey and honored to be on the forefront of psychedelic medicine research. Rebecca earned her B.A. from UC Berkeley in 2000.

She resides in Northern California CA alongside her husband, two daughters and the family labradoodle and can be found starting impromptu dance parties, enjoying delicious tacos and playing in nature with family and friends.

Shannon Clare Carlin, M.A., A.M.F.T.

Shannon Clare Carlin, M.A., A.M.F.T. Director of Training and Supervision

Read Bio
Shannon Clare Carlin, M.A., A.M.F.T.

Shannon Clare Carlin, M.A., A.M.F.T.

Director of Training and Supervision

Shannon Carlin, M.A., AMFT, is the Associate Director of Training and Supervision at the MAPS Public Benefit Corporation (MAPS PBC), a wholly owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), a 501(c)(3) non-profit. As the Associate Director of Training and Supervision, Shannon oversees the development and implementation of the programs that provide training and supervision to prepare mental health and medical professionals to deliver MDMA-assisted psychotherapy in approved clinical settings. Shannon started working with MAPS in 2011 before joining MAPS PBC in 2016.

In her dedication to supporting people through growth and healing, Shannon has served as a co-therapist on MAPS-sponsored Phase 2 trials researching MDMA-assisted psychotherapy for anxiety associated with life-threatening illness and MDMA-assisted psychotherapy for severe PTSD. Shannon’s direct clinical work continues to inform the development and implementation of the training programs she oversees.

Shannon’s previous professional experience includes the development of community programs delivering resources, services, training, and support for healthy living, life skills, employment, and positive youth development. Her work has served adults with schizophrenia, bipolar, and substance use disorder, families and youth in a low-income residential setting, and high school students learning about moderation management of drug and alcohol use. In her lifelong commitment to address homelessness, Shannon volunteers with housing projects and shelters and completed a farm internship with the Homeless Garden Project.

Shannon received her master’s degree in Integral Counseling Psychology from the California Institute of Integral Studies and a bachelor’s degree in Cultural Anthropology from the University of California, Santa Cruz. An adventurer at heart, Shannon can be found in nature, backpacking, running, and dancing. She celebrates and cultivates relationship and community and is passionate about life, love, and thriving.

 

Heather Clouting, M.Sc.

Heather Clouting, M.Sc. Director of CMC and Project Management

Read Bio
Heather Clouting, M.Sc.

Heather Clouting, M.Sc.

Director of CMC and Project Management

Heather Clouting earned a bachelor’s degree in Chemistry in 2002 from Kingston University London, UK and a master’s degree in Clinical Trials in 2009 from the London School of Hygiene and Tropical Medicine, UK. Prior to joining MAPS Public Benefit Corporation (MAPS PBC) as a consultant, Heather worked as a Project Delivery Lead at GSK, Lead Senior Clinical Trial Leader and Associate Director, Clinical Operations Manager at Novartis Vaccines and Clinical Trial Manager at the Medical Research Council, Clinical Trials Unit, London.

At MAPS PBC, Heather manages the Phase 3 and Commercial MDMA drug manufacture, supply, and Chemistry Manufacturing and Controls (CMC) regulatory writing for submission to relevant Regulatory and Health Authorities.

Heather is passionate and excited about the field of psychedelic research for mental health and the potential benefits that can be afforded to patients for which current options are limited, especially outside of the usual for-profit model of healthcare. Heather joined MAPS PBC to use her combined experience of over 13 years in the public and private sectors of clinical research to support this important mission and help drive forward the potential licensure of MDMA for posttraumatic stress disorder (PTSD).

 

 

MAPS Public Benefit Corporation

Our Mission
Who We Are
Careers
News
FAQ
Contact Us

1115 Mission Street
Santa Cruz, CA 95060-9989

MAPS PBC is a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS). MAPS is a 501(c)(3) non-profit research and educational organization.